Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to $8.2 million.

  • Heron Therapeutics' Gains from Investment Securities rose 10.45% to $28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.9 million, marking a year-over-year increase of 10.45%. This contributed to the annual value of $8.2 million for FY2024, which is 49.67% down from last year.
  • According to the latest figures from FY2024, Heron Therapeutics' Gains from Investment Securities is $8.2 million, which was down 49.67% from $16.2 million recorded in FY2023.
  • Over the past 5 years, Heron Therapeutics' Gains from Investment Securities peaked at $16.2 million during FY2023, and registered a low of $2.1 million during FY2021.
  • For the 3-year period, Heron Therapeutics' Gains from Investment Securities averaged around $9.9 million, with its median value being $8.2 million (2024).
  • As far as peak fluctuations go, Heron Therapeutics' Gains from Investment Securities spiked by 206.06% in 2023, and later tumbled by 49.67% in 2024.
  • Heron Therapeutics' Gains from Investment Securities (Yearly) stood at $3.2 million in 2020, then crashed by 35.81% to $2.1 million in 2021, then skyrocketed by 157.87% to $5.3 million in 2022, then surged by 206.06% to $16.2 million in 2023, then tumbled by 49.67% to $8.2 million in 2024.